作者: M. Margelí , B. Cirauqui , E. Castellà , G. Tapia , C. Costa
DOI: 10.1200/JCO.2008.26.15_SUPPL.11510
关键词:
摘要: The invention relates to methods for predicting the clinical outcome of a patient which suffers from breast cancer based on expression levels BRCA1, wherein low BRCA1 are indicative good prognosis. Moreover, response neoadjuvant therapy combination an anti-metabolite, intercalating agent and alkylating agentof BRCA1.